Caplin Point Laboratories Limited (CAPLIPOINT) — regulation 31 | 16 June 2026

StockFin.ai

Try Free

📢 Key Event
Declaration of no share encumbrance under SEBI Regulation 31(4)

💡 Investor Takeaway
Shareholding structure remains clean with no new encumbrances, reducing takeover risk.

Caplin Point Laboratories disclosed on April 6, 2026, that no encumbrance on its shares was created during the financial year ended March 31, 2026, as required under SEBI Takeover Regulations Regulation 31(4). The filing confirms promoter and promoter group holdings remain unencumbered, supporting compliance with takeover norms.

📄 View Original Announcement (PDF)

📊 Stock Analysis — CAPLIPOINT ✨ Ask AI About This

About Caplin Point Laboratories Limited (CAPLIPOINT)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹15,193.22 Cr P/E: 29.5

View full CAPLIPOINT stock details →

📡 Get AI alerts when CAPLIPOINT files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CAPLIPOINT — Free

💡 Ask AI about this filing

"How does this affect CAPLIPOINT margins?" "Compare with last quarter results" "What should investors watch for?"

Ask AI Free →

📊 More CAPLIPOINT filings

See all CAPLIPOINT filings →

🔥 Also filed on 16 June 2026

HEIDELBERG HeidelbergCement India Limited Announcement DEN Den Networks Limited Announcement GRINFRA G R Infraprojects Limited Announcement GICRE General Insurance Corporation of India Offer Document BOSCH-HCIL BOSCH HOME COMFORT INDIA LIMITED Announcement HDFCBANK HDFC Bank Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when CAPLIPOINT files new disclosures

Track CAPLIPOINT filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track CAPLIPOINT — Free

Free account · 2 AI queries/day